Skip to content

Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders

Recombinant hCG (Ovitrelle) Vesrus Urinary hCG (Pregnyl) for Triggering Final Oocyte Maturation in High Responders

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00415766
Enrollment
150
Registered
2006-12-25
Start date
2013-06-30
Completion date
2016-07-31
Last updated
2016-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

recombinant hCG, urinary hCG

Brief summary

The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.

Detailed description

Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte maturation and to trigger ovulation in assisted conception. Recombinant technology has allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this would allow the safe subcutaneous administration of a compound with less batch-to-batch variation. This study will investigate the effectiveness of the recombinant hCG compared to the currently used urinary hCG.

Interventions

DRUGrHCG 250ug

Injection of 250 ug Ovitrelle to trigger final oocyte maturation

DRUGuHCG 5000 IU

Injection of 5000 IU Pregnyl to trigger final oocyte maturation

DRUGuHCG 7500 IU

Injection of 7500 IU Pregnyl to trigger final oocyte maturation

Sponsors

Eugonia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* At least 14 follicles \>11mm on the day of triggering final oocyte maturation * Pretreated with GnRH antagonist protocol

Exclusion criteria

* Poor responders * Women with 25 or more follicles on the day of trigger

Design outcomes

Primary

MeasureTime frameDescription
Percentage of mature oocytesDay of oocyte retrieval (Day 0)Percentage MII/COCs

Secondary

MeasureTime frameDescription
Clinical pregnancy per embryo transfer7 weeks of gestation
Ongoing pregnancy per embryo transfer12 weeks of gestation
Level of serum hCG on day of oocyte retrievalDay of oocyte retrieval
Positive test per embryo transfer15 days post oocyte retrieval
Number of mature oocytes (MII)Day of oocyte retrieval
Oocyte retrieval rateDay of oocyte retrieval (Day 0)Number of oocytes retrieved/number of follicles on the day of triggering final oocyte maturation
Incidence of severe early OHSSup to Day 5 post oocyte retrieval
Number of oocytes (COC) retrievedDay of oocyte retrieval

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026